Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 7.42%1.54T | 2.91%6.08T | 0.38%1.57T | 2.66%1.58T | 3.98%1.5T | 4.97%1.43T | 3.89%5.91T | 3.28%1.57T | 6.02%1.54T | 5.77%1.45T |
Cost of revenue | 6.81%762.33B | -1.36%3.15T | -7.95%858.02B | -0.53%826.12B | -0.28%752.77B | 5.49%713.74B | 10.56%3.19T | 13.27%932.08B | 11.72%830.5B | 12.93%754.89B |
Gross profit | 8.03%773.39B | 7.93%2.93T | 12.60%714.42B | 6.41%751.69B | 8.62%751.32B | 4.46%715.93B | -2.98%2.72T | -8.57%634.46B | 0.03%706.41B | -1.08%691.67B |
Operating expense | -0.03%469.47B | 24.10%2.06T | 2.51%570.28B | 152.84%534.14B | 8.33%483.25B | 5.74%469.61B | -9.71%1.66T | 3.94%556.3B | -54.25%211.25B | 8.42%446.1B |
Selling and administrative expenses | 6.62%510.2B | 5.96%2.08T | 4.04%575.49B | 5.18%535.49B | 8.49%492.28B | 6.67%478.52B | 5.70%1.96T | 2.64%553.14B | 10.26%509.11B | 6.38%453.73B |
-General and administrative expense | 6.62%510.2B | 5.96%2.08T | 4.04%575.49B | 5.18%535.49B | 8.49%492.28B | 6.67%478.52B | 5.70%1.96T | 2.64%553.14B | 10.26%509.11B | 6.38%453.73B |
Other operating expenses | 58.41%2.46B | -61.01%5.69B | 31.17%4.14B | ---- | ---- | --1.55B | 495.92%14.59B | --3.15B | --2.45B | --8.98B |
Total other operating income | 312.99%43.2B | -90.61%30.17B | --9.34B | -99.55%1.35B | -45.70%9.03B | 132.68%10.46B | 1,174.47%321.42B | --0 | --300.31B | 10.35%16.62B |
Operating profit | 23.39%303.93B | -17.37%876.07B | 84.40%144.14B | -56.07%217.55B | 9.16%268.07B | 2.09%246.32B | 9.80%1.06T | -50.75%78.17B | 102.55%495.15B | -14.66%245.57B |
Net non-operating interest income (expenses) | -236.13%-33.18B | 53.95%-48.49B | 104.63%1.01B | 43.21%-22.65B | 36.76%-16.99B | 40.95%-9.87B | -290.45%-105.31B | -4,359.06%-21.85B | -256.98%-39.88B | -140.45%-26.86B |
Non-operating interest income | -41.92%4.51B | 8.53%12.92B | -2.99%5.67B | 140.30%1.61B | -57.33%2.14B | 81.38%7.77B | -69.84%11.91B | -65.36%5.85B | -87.40%670M | -18.04%5.01B |
Non-operating interest expense | 113.65%37.7B | -47.60%61.42B | -83.17%4.66B | -40.18%24.26B | -39.99%19.13B | -16.00%17.64B | 76.41%117.21B | 69.20%27.7B | 145.92%40.55B | 84.40%31.87B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -99.93%8M | 107.41%3.46B | 67.83%-4.57B | 45.67%-5.41B | 109.02%1.27B | 233.57%12.17B | 8.60%-46.77B | -23.42%-14.2B | 46.58%-9.96B | 9.28%-14.08B |
Special income (charges) | 3.16B | 44.44%-25.13B | -598.72%-25.13B | 0 | 0 | 0 | -53.82%-45.23B | -619.20%-3.6B | -8.31%-31.3B | -10.33B |
Less:Other special charges | ---3.16B | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Less:Write off | ---- | -44.44%25.13B | 598.72%25.13B | --0 | --0 | ---- | 53.82%45.23B | 619.20%3.6B | 8.31%31.3B | --10.33B |
Other non-operating income (expenses) | ||||||||||
Income before tax | 10.17%273.91B | -6.60%805.91B | 199.72%115.45B | -54.23%189.49B | 29.88%252.35B | 15.08%248.62B | 0.57%862.87B | -73.83%38.52B | 122.89%414.01B | -25.57%194.3B |
Income tax | -2.26%73.34B | 3.31%215.65B | 72.18%27.86B | 30.44%59.63B | -30.60%53.12B | 6.74%75.04B | -26.13%208.74B | -64.01%16.18B | -24.60%45.71B | -6.42%76.55B |
Net income | 15.55%200.57B | -9.76%590.27B | 292.09%87.59B | -64.74%129.86B | 69.20%199.23B | 19.11%173.58B | 13.68%654.13B | -78.15%22.34B | 194.36%368.3B | -34.31%117.75B |
Net income continuous operations | 15.55%200.57B | -9.76%590.27B | 292.09%87.59B | -64.74%129.86B | 69.20%199.23B | 19.11%173.58B | 13.68%654.13B | -78.15%22.34B | 194.36%368.3B | -34.31%117.75B |
Noncontrolling interests | 41.67%38.06B | -17.57%101.19B | 1,338.57%5.2B | -73.04%25.32B | 312.21%43.81B | 44.23%26.87B | 110.36%122.76B | -106.13%-420M | 747.47%93.93B | -53.72%10.63B |
Net income attributable to the company | 10.76%162.51B | -7.96%489.07B | 262.00%82.39B | -61.90%104.54B | 45.09%155.42B | 15.43%146.72B | 2.76%531.37B | -76.14%22.76B | 140.61%274.37B | -31.46%107.12B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 10.76%162.51B | -7.96%489.07B | 262.00%82.39B | -61.90%104.54B | 45.09%155.42B | 15.43%146.72B | 2.76%531.37B | -76.14%22.76B | 140.61%274.37B | -31.46%107.12B |
Gross dividend payment | ||||||||||
Basic earnings per share | 10.75%3.432 | -8.32%10.317 | 264.15%1.737 | -62.10%2.2 | 44.60%3.281 | 14.86%3.099 | 2.26%11.253 | -76.46%0.477 | 139.34%5.804 | -31.80%2.269 |
Diluted earnings per share | 10.13%3.38 | -8.86%10.116 | 262.72%1.683 | -62.72%2.142 | 44.18%3.221 | 15.16%3.069 | 2.61%11.1 | -77.10%0.464 | 141.89%5.745 | -31.51%2.234 |
Dividend per share | 0 | 0.00%8.6 | 0.00%4.3 | 0 | 0.00%4.3 | 0 | 0.00%8.6 | 0.00%4.3 | 0 | 0.00%4.3 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |